News
& Events
News
& Events

News
& Events

Inversago Pharma Initiates a Phase 1 Clinical Trial on INV-202, a Next Generation Peripherally-acting CB1 Blocker

MONTREAL (CANADA) – September 7th, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL) from Health Canada on July 29, 2021, it has dosed the first volunteers with INV-202 in its first-in-human phase 1 clinical trial, which will […]

Read more

Inversago Pharma to present at upcoming Oppenheimer Rare & Orphan Disease Summit to be held on Friday, May 21, 2021

MONTREAL (CANADA) – May 20, 2021 – Inversago Pharma Inc., the peripheral CB1 blockade company, today announced that François Ravenelle, PhD, CEO and Founder, will be presenting at the Oppenheimer Rare & Orphan Disease Summit. Details are as follows: Date: Friday, May 21, 2021 Time: 2:55 pm ET Format: 40-minute live virtual presentation About the […]

Read more

Inversago Pharma to present at upcoming Bloom Burton & Co. Healthcare Investor Conference to be held on April 20-21, 2021

MONTREAL (CANADA) – March 30, 2021 – Inversago Pharma Inc., the peripheral CB1 blockade company, today announced that François Ravenelle, PhD, CEO and Founder, will be presenting at the Bloom Burton & Co. Healthcare Investor Conference. Details are as follows: Date: Wednesday, April 21, 2021 Time: 4 pm ET Format: 30-minute live virtual presentation, including […]

Read more

Inversago Pharma Receives Rare Pediatric Disease Designation from the FDA for INV-101 for the Treatment of Prader-Willi Syndrome

MONTREAL (CANADA) – January 07, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced the U.S. Food and Drug Administration (FDA) granted a Rare Pediatric Disease (RPD) designation to the Company’s lead compound, INV-101, for the treatment of Prader-Willi syndrome (PWS). A Phase I study with INV-101 is […]

Read more